Small interfering RNA-based molecular therapy of cancers.

Author: Wei GUO ^{1
,

2} ; Wangbing CHEN ; Wendan YU ; Wenlin HUANG ; Wuguo DENG
Author Information

1. State Key Laboratory of Oncology in South China
2. Research Department, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P. R. China. dengwg@sysucc.org.cn.
Publication Type:Journal Article
MeSH: Animals; Clinical Trials as Topic; Drug Carriers; Drug Evaluation, Preclinical; Gene Targeting; Genetic Therapy; methods; Gold; chemistry; Humans; Nanoparticles; Neoplasms; genetics; therapy; RNA Interference; RNA, Small Interfering; genetics
From:Chinese Journal of Cancer 2013;32(9):488-493
CountryChina
Language:English
Abstract: RNA interference (RNAi) has become a gold standard for validating gene function in basic life science research and provides a promising therapeutic modality for cancer and other diseases. This mini-review focuses on the potential of small interfering RNAs (siRNAs) in anticancer treatment, including the establishment and screening of cancer-associated siRNA libraries and their applications in anticancer drug target discovery and cancer therapy. This article also describes the current delivery approaches of siRNAs using lipids, polymers, and, in particular, gold nanoparticles to induce significant gene silencing and tumor growth regression.